8009 related articles for article (PubMed ID: 1779176)
1. Attempts to optimize active specific immunotherapy for melanoma.
Mitchell MS
Int Rev Immunol; 1991; 7(4):331-47. PubMed ID: 1779176
[TBL] [Abstract][Full Text] [Related]
2. Active specific immunotherapy of melanoma with allogeneic cell lysates. Rationale, results, and possible mechanisms of action.
Mitchell MS; Harel W; Kan-Mitchell J; LeMay LG; Goedegebuure P; Huang XQ; Hofman F; Groshen S
Ann N Y Acad Sci; 1993 Aug; 690():153-66. PubMed ID: 8368734
[TBL] [Abstract][Full Text] [Related]
3. Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy.
Kan-Mitchell J; Huang XQ; Steinman L; Oksenberg JR; Harel W; Parker JW; Goedegebuure PS; Darrow TL; Mitchell MS
Cancer Immunol Immunother; 1993 Jul; 37(1):15-25. PubMed ID: 8513449
[TBL] [Abstract][Full Text] [Related]
4. Association of HLA phenotype with response to active specific immunotherapy of melanoma.
Mitchell MS; Harel W; Groshen S
J Clin Oncol; 1992 Jul; 10(7):1158-64. PubMed ID: 1607920
[TBL] [Abstract][Full Text] [Related]
5. MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele.
Crowley NJ; Darrow TL; Quinn-Allen MA; Seigler HF
J Immunol; 1991 Mar; 146(5):1692-9. PubMed ID: 1671580
[TBL] [Abstract][Full Text] [Related]
6. Cloned human cytotoxic T lymphocyte (CTL) lines reactive with autologous melanoma cells. I. In vitro generation, isolation, and analysis to phenotype and specificity.
de Vries JE; Spits H
J Immunol; 1984 Jan; 132(1):510-9. PubMed ID: 6197458
[TBL] [Abstract][Full Text] [Related]
7. Detection of melanoma-reactive CD4+ HLA-class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma.
LeMay LG; Kan-Mitchell J; Goedegebuure P; Harel W; Mitchell MS
Cancer Immunol Immunother; 1993 Aug; 37(3):187-94. PubMed ID: 8101473
[TBL] [Abstract][Full Text] [Related]
8. Tumor associated antigens in human renal cell carcinoma: MHC restricted recognition by cytotoxic T lymphocytes.
Bernhard H; Jäger E; Maeurer MJ; Meyer zum Büschenfelde KH; Knuth A
Tissue Antigens; 1996 Jul; 48(1):22-31. PubMed ID: 8864171
[TBL] [Abstract][Full Text] [Related]
9. HLA restriction and T-cell-receptor V beta gene expression of cytotoxic T lymphocytes reactive with human squamous-cell carcinoma of the head and neck.
Yasumura S; Weidmann E; Hirabayashi H; Johnson JT; Herberman RB; Whiteside TL
Int J Cancer; 1994 May; 57(3):297-305. PubMed ID: 8168988
[TBL] [Abstract][Full Text] [Related]
10. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
[TBL] [Abstract][Full Text] [Related]
11. A preclinical model to assess the antigenicity of an HLA-A2 melanoma cell vaccine.
Hayashi Y; Hoon DS; Foshag LJ; Park MS; Terasaki PI; Morton DL
Cancer; 1993 Aug; 72(3):750-9. PubMed ID: 8334627
[TBL] [Abstract][Full Text] [Related]
12. The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens.
Darrow TL; Slingluff CL; Seigler HF
J Immunol; 1989 May; 142(9):3329-35. PubMed ID: 2785141
[TBL] [Abstract][Full Text] [Related]
13. Melanoma cells and normal melanocytes share antigens recognized by HLA-A2-restricted cytotoxic T cell clones from melanoma patients.
Anichini A; Maccalli C; Mortarini R; Salvi S; Mazzocchi A; Squarcina P; Herlyn M; Parmiani G
J Exp Med; 1993 Apr; 177(4):989-98. PubMed ID: 8459226
[TBL] [Abstract][Full Text] [Related]
14. Induction of CD4+ cytotoxic T cells by sensitization with allogeneic melanomas bearing shared or cross-reactive HLA-A.
Hayashi Y; Hoon DS; Park MS; Terasaki PI; Foshag LJ; Morton DL
Cell Immunol; 1992 Feb; 139(2):411-25. PubMed ID: 1733512
[TBL] [Abstract][Full Text] [Related]
15. Analysis of antigens recognized on human melanoma cells by A2-restricted cytolytic T lymphocytes (CTL).
Wölfel T; Hauer M; Klehmann E; Brichard V; Ackermann B; Knuth A; Boon T; Meyer Zum Büschenfelde KH
Int J Cancer; 1993 Sep; 55(2):237-44. PubMed ID: 7690346
[TBL] [Abstract][Full Text] [Related]
16. Immunosensitization of melanoma tumor cells to non-MHC Fas-mediated killing by MART-1-specific CTL cultures.
Frost PJ; Butterfield LH; Dissette VB; Economou JS; Bonavida B
J Immunol; 2001 Mar; 166(5):3564-73. PubMed ID: 11207317
[TBL] [Abstract][Full Text] [Related]
17. Active-specific immunotherapy for melanoma.
Mitchell MS; Harel W; Kempf RA; Hu E; Kan-Mitchell J; Boswell WD; Dean G; Stevenson L
J Clin Oncol; 1990 May; 8(5):856-69. PubMed ID: 2139701
[TBL] [Abstract][Full Text] [Related]
18. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6.
Maeurer MJ; Gollin SM; Storkus WJ; Swaney W; Karbach J; Martin D; Castelli C; Salter R; Knuth A; Lotze MT
Clin Cancer Res; 1996 Apr; 2(4):641-52. PubMed ID: 9816214
[TBL] [Abstract][Full Text] [Related]
19. Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones.
Bernhard H; Karbach J; Wölfel T; Busch P; Störkel S; Stöckle M; Wölfel C; Seliger B; Huber C; Meyer zum Büschenfelde KH
Int J Cancer; 1994 Dec; 59(6):837-42. PubMed ID: 7989126
[TBL] [Abstract][Full Text] [Related]
20. Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients.
Valmori D; Liénard D; Waanders G; Rimoldi D; Cerottini JC; Romero P
Cancer Res; 1997 Feb; 57(4):735-41. PubMed ID: 9044853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
